GB28547 - Lebrikizumab in patients with idiopathic pulmonary fibrosis

• Research type

  Research Study

• Full title

  A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

• IRAS ID

  135637

• Contact name

  Toby M Maher

• Contact email

  t.maher@rbht.nhs.uk

• Sponsor organisation

  F Hoffmann-La Roche Ltd

• Eudract number

  2013-001163-24

• ISRCTN Number

  n/a

• Research summary

  Permission to publish the Research Summary not granted at this time.  The Research Summary of the above study can be found at: <a title="Roche trials website" href="http://www.roche-trials.com/" target="_blank" class="oLinkExternal">http://www.roche-trials.com/</a>

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/1321

• Date of REC Opinion

  14 Oct 2013

• REC opinion

  Further Information Favourable Opinion